1
|
Dansey R. Abstract IA18: Clinical validation of PI3Kδ as a therapeutic target in B-cell malignancy. Mol Cancer Ther 2015. [DOI: 10.1158/1538-8514.pi3k14-ia18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Idelalisib (ZYDELIG®, GS-1101) is a first-in-class, targeted, highly selective, oral inhibitor of PI3Kδ that reduces proliferation, enhances apoptosis, and inhibits homing and retention of malignant B cells in lymphoid tissues (Lannutti et al, 2011). We studied idelalisib in 2 registrational trials, one in relapsed chronic lymphocytic leukemia (CLL) and one in refractory, indolent non-Hodgkin lymphoma (iNHL). In the Phase 3 CLL trial (Furman 2014), patients with relapsed disease and multiple co-morbidities precluding the use of chemotherapy were randomized to receive blinded idelalisib 150 mg BID plus rituximab intravenously (at a dose of 375 mg per square meter, followed by 500 mg per square meter every 2 weeks for 4 doses and then every 4 weeks for 3 doses) for a total of 8 infusions or an oral placebo plus rituximab. A total of 220 patients were randomized, with a median age of 71 yrs (78% ≥65 yrs), median time since diagnosis of 8.5 yrs, and median number of 3 prior therapies (range: 1-12). Of these, 44% of pts had del17p/TP53 mutation. The median progression-free survival was 5.5 months in the placebo group and was not reached in the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P<0.001). Patients receiving idelalisib versus those receiving placebo had improved rates of overall response (81% vs. 13%; odds ratio, 29.92; P<0.001) and overall survival at 12 months (92% vs. 80%; hazard ratio for death, 0.28; P = 0.02). IDELA+R retained robust efficacy across all high-risk subpopulations and achieved 76.5% ORR and PFS HR 0.13 in the highest risk patients who were positive for both 17p deletion and TP53 mutation. The Phase 2 iNHL study (Gopal 2014) enrolled 125 heavily pretreated patients with disease refractory to rituximab and alkylating agents to receive single agent idelalisib 150 mg BID. The median age of the patients was 64 yrs (range, 33 to 87); patients had received a median of four prior therapies (range, 2 to 12). The predominate iNHL subtype was follicular lymphoma (72 patients), followed by small lymphocytic lymphoma (28), marginal-zone lymphoma (15), and Waldenström's macroglobulinemia (10). The overall response rate was 57%. Responses were rapid (median time to a response was 1.9 months) and the median duration of response was 12.5 months. Median progression-free survival was 11 months. Key safety findings across the idelalisib program include an early transient hepatotoxicity characterized by elevations in serum transaminases (≥ Grade 3) occurring in 14% of treated subjects, late onset (≥ Grade 3) severe diarrhea/colitis, also occurring in 14% of subjects, and pneumonitis of any grade, occurring in 3% of subjects. Additional trials of idelalisib in combination with other chemoimmunotherapy are ongoing in both CLL and iNHL, including studies in patients with previously untreated disease. Future development plans include establishing the role of PI3Kδ inhibition in solid tumors and testing the activity of idelalisib against a range of hematologic malignancies.
Citation Format: Roger Dansey. Clinical validation of PI3Kδ as a therapeutic target in B-cell malignancy. [abstract]. In: Proceedings of the AACR Special Conference: Targeting the PI3K-mTOR Network in Cancer; Sep 14-17, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(7 Suppl):Abstract nr IA18.
Collapse
|
2
|
Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013; 31:3800-6. [PMID: 24043751 DOI: 10.1200/jco.2012.44.6716] [Citation(s) in RCA: 163] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
PURPOSE Denosumab, an anti-RANK ligand monoclonal antibody, significantly increases bone metastasis-free survival (BMFS; hazard ratio [HR], 0.85; P = .028) and delays time to first bone metastasis in men with nonmetastatic castration-resistant prostate cancer (CRPC) and baseline prostate-specific antigen (PSA) ≥ 8.0 ng/mL and/or PSA doubling time (PSADT) ≤ 10.0 months. To identify men at greatest risk for bone metastasis or death, we evaluated relationships between PSA and PSADT with BMFS in the placebo group and the efficacy and safety of denosumab in men with PSADT ≤ 10, ≤ 6, and ≤ 4 months. PATIENTS AND METHODS A total of 1,432 men with nonmetastatic CRPC were randomly assigned 1:1 to monthly subcutaneous denosumab 120 mg or placebo. Enrollment began February 2006; primary analysis cutoff was July 2010, when approximately 660 men were anticipated to have developed bone metastases or died. RESULTS In the placebo group, shorter BMFS was observed as PSADT decreased below 8 months. In analyses by shorter baseline PSADT, denosumab consistently increased BMFS by a median of 6.0, 7.2, and 7.5 months among men with PSADT ≤ 10 (HR, 0.84; P = .042), ≤ 6 (HR, 0.77; P = .006), and ≤ 4 months (HR, 0.71; P = .004), respectively. Denosumab also consistently increased time to bone metastasis by PSADT subset. No difference in survival was observed between treatment groups for the overall study population or PSADT subsets. CONCLUSION Patients with shorter PSADT are at greater risk for bone metastasis or death. Denosumab consistently improves BMFS in men with shorter PSADT and seems to have the greatest treatment effects in men at high risk for progression.
Collapse
Affiliation(s)
- Matthew R Smith
- Matthew R. Smith, Massachusetts General Hospital Cancer Center, Boston, MA; Fred Saad, University of Montreal Hospital Center, Montreal, Quebec, Canada; Stephane Oudard, Georges Pompidou Hospital, Paris; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Neal Shore, Carolina Urological Research Center, Myrtle Beach, SC; Paul Sieber, Urological Associates of Lancaster, Lancaster, PA; Bertrand Tombal, Université Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Belgium; Ronaldo Damiao, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil; Gavin Marx, Sydney Haematology and Oncology Clinic, University of Sydney, Wahroonga, New South Wales, Australia; Kurt Miller, Charité Berlin, Berlin, Germany; Peter Van Veldhuizen, Kansas City Veterans Affairs Medical Center, Kansas City, MO; Juan Morote, Hospital Vall d'Hebron, Barcelona, Spain; and Zhishen Ye, Roger Dansey, and Carsten Goessl, Amgen, Thousand Oaks, CA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Stopeck A, Henry D, Dansey R, Qian Y, Cong Z, Arellano J. Authors' response to letter to the editor. J Med Econ 2013; 16:262-3. [PMID: 23424726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
|
4
|
Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K. Pain outcomes in patients with advanced breast cancer and bone metastases. Cancer 2012; 119:832-8. [DOI: 10.1002/cncr.27789] [Citation(s) in RCA: 108] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2012] [Accepted: 07/11/2012] [Indexed: 01/01/2023]
|
5
|
Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, Fallowfield L, Fujiwara Y, Jassem J, Paterson AHG, Ritchie D, Steger GG, Stopeck A, Vogel C, Fan M, Jiang Q, Chung K, Dansey R, Braun A. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res 2012; 18:4841-9. [PMID: 22893628 DOI: 10.1158/1078-0432.ccr-11-3310] [Citation(s) in RCA: 88] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Denosumab was shown to be superior to zoledronic acid in preventing skeletal related events (SRE) in patients with breast cancer and bone metastases in a randomized, double-blind phase III study. We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL). EXPERIMENTAL DESIGN Patients were randomized 1:1 to receive subcutaneous denosumab 120 mg (n = 1,026) and intravenous placebo, or intravenous zoledronic acid 4 mg (n = 1,020) and subcutaneous placebo every 4 weeks. Analyses reported here include the proportion of patients with one or multiple on-study SREs, time to first radiation to bone, time to first SRE or hypercalcemia of malignancy, and change in HRQoL (functional assessment of cancer therapy-general). RESULTS Fewer patients receiving denosumab than zoledronic acid had an on-study SRE (31% vs. 36%, P = 0.006). The incidence of first radiation to bone was 12% (n = 123) with denosumab versus 16% (n = 162) with zoledronic acid. Denosumab prolonged the time to first radiation to bone by 26% versus zoledronic acid (HR, 0.74; 95% confidence interval [CI], 0.59-0.94, P = 0.012) and prolonged the time to first SRE or hypercalcemia of malignancy by 18% (HR, 0.82; 95% CI, 0.70-0.95; P = 0.007). Ten percent more patients had a clinically meaningful improvement in HRQoL with denosumab relative to zoledronic acid, regardless of baseline pain levels. CONCLUSIONS Denosumab was superior to zoledronic acid in reducing bone-related complications of metastatic breast cancer and maintained HRQoL, providing an efficacious, well-tolerated treatment option for patients with bone metastases from breast cancer.
Collapse
Affiliation(s)
- Miguel Martin
- Complutense University and Hospital General Universitario Gregorio Maranon, Servicio De Oncologia Medica, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Goessl C, Katz L, Dougall WC, Kostenuik PJ, Zoog HB, Braun A, Dansey R, Wagman RB. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction. Ann N Y Acad Sci 2012; 1263:29-40. [PMID: 22831177 DOI: 10.1111/j.1749-6632.2012.06674.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Denosumab is a fully human monoclonal antibody against RANK ligand (RANKL), an essential cytokine for the formation, function, and survival of osteoclasts. The role of excessive RANKL as a contributor to conditions characterized by bone loss or bone destruction has been well studied. With its novel mechanism of action, denosumab offers a significant advance in the treatment of postmenopausal osteoporosis; bone loss associated with hormone ablation therapy in women with breast cancer and men with prostate cancer; and the prevention of skeletal-related events in patients with bone metastases from solid tumors by offering clinical benefit to these patients in need.
Collapse
|
7
|
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23:1341-1347. [PMID: 21986094 DOI: 10.1093/annonc/mdr435] [Citation(s) in RCA: 477] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Osteonecrosis of the jaw (ONJ) has been reported in patients receiving bisphosphonates for metastatic bone disease. ONJ incidence, risk factors, and outcomes were evaluated in a combined analysis of three phase III trials in patients with metastatic bone disease receiving antiresorptive therapies. PATIENTS AND METHODS Patients with bone metastases secondary to solid tumors or myeloma were randomly assigned to receive either s.c. denosumab (120 mg) or i.v. zoledronic acid (4 mg) every 4 weeks. On-study oral examinations were conducted by investigators at baseline and every 6 months. Oral adverse events were adjudicated by an independent blinded committee of dental experts. RESULTS Of 5723 patients enrolled, 89 (1.6%) patients were determined to have ONJ: 37 (1.3%) received zoledronic acid and 52 (1.8%) received denosumab (P = 0.13). Tooth extraction was reported for 61.8% of patients with ONJ. ONJ treatment was conservative in >95% of patients. As of October 2010, ONJ resolved in 36.0% of patients (29.7% for zoledronic acid and 40.4% for denosumab). CONCLUSIONS In this combined analysis of three prospective trials, ONJ was infrequent, management was mostly conservative, and healing occurred in over one-third of the patients. Educating physicians about oral health before and during bone-targeted therapy may help reduce ONJ incidence and improve outcomes.
Collapse
Affiliation(s)
- F Saad
- Department of Urology, University of Montreal Montreal, Canada.
| | - J E Brown
- Cancer Research UK Clinical Centre, University of Leeds, Leeds, UK
| | - C Van Poznak
- Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - T Ibrahim
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
| | - S M Stemmer
- Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel
| | - A T Stopeck
- Department of Medicine, University of Arizona, Arizona Cancer Center, Tucson, USA
| | - I J Diel
- Institute for Gynecologic Oncology, Center for Comprehensive Gynecology, Mannheim, Germany
| | - S Takahashi
- The Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - N Shore
- Carolina Urologic Research Center, Myrtle Beach
| | - D H Henry
- Joan Karnell Cancer Center, Pennsylvania Hospital, Philadelphia, USA
| | - C H Barrios
- Internal Medicine Department, Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Rio Grande do Sul, Brazil
| | - T Facon
- Department of Blood Diseases, Hôpital Claude Huriez, Lille, France
| | - F Senecal
- Northwest Medical Specialties Tacoma, USA
| | - K Fizazi
- Department of Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - L Zhou
- Global Biostatistical Sciences
| | | | | | - R Dansey
- Clinical Development, Amgen Inc., Thousand Oaks, USA
| |
Collapse
|
8
|
Smith MR, Saad F, Shore ND, Oudard S, Miller K, Tombal B, Sieber P, Fizazi K, Van Veldhuizen PJ, Damião R, Marx GM, Morote J, Feng A, Dansey R, Goessl CD. Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.5_suppl.6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6 Background: Denosumab, an anti-RANK-ligand monoclonal antibody, has been shown to prolong BMFS by a median 4.2 months and with a 15% risk reduction vs. placebo in men with non-metastatic CRPC and baseline PSA value ≥ 8.0 ng/mL and/or PSA doubling time (DT) ≤ 10.0 months. To determine the efficacy of denosumab in men at greatest risk for bone metastases, we evaluated BMFS in a subset of men with PSADT < 6 months, a cutoff based on a previous report (Smith MR, et al: J Clin Oncol. 23:2918-2925, 2005). Methods: 1432 men with non-metastatic CRPC (baseline [median] PSA: 12.3 ng/mL, PSADT: 5.1 months, ADT duration: 47.1 months) were randomized 1:1 to receive monthly subcutaneous denosumab 120 mg or placebo. The first patient enrolled February 2006; primary analysis cut-off was July 2010, when > 660 men had developed bone metastasis or died. The primary endpoint was BMFS (time to first bone metastasis or death from any cause). BMFS results are presented for men with baseline PSADT < 6 months. Results: Median BMFS in the placebo group of men with PSADT < 6 months was 6.5 months shorter than for the placebo group in the full population (18.7 months vs. 25.2 months), indicating that these men are at particularly high risk. In this group of men with PSADT < 6 months, denosumab prolonged BMFS by a median of 7.2 months and with a 23% reduction in risk compared with placebo (Table). Conclusions: Patients with shortened PSADT are at higher risk of developing bone metastasis and denosumab is markedly effective at prolonging BMFS in this subset of patients. [Table: see text]
Collapse
Affiliation(s)
- Matthew R. Smith
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Fred Saad
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Neal D. Shore
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Stephane Oudard
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Kurt Miller
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Bertrand Tombal
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Paul Sieber
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Karim Fizazi
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Peter J. Van Veldhuizen
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Ronaldo Damião
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Gavin M. Marx
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Juan Morote
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Amy Feng
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Roger Dansey
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| | - Carsten Dietrich Goessl
- Massachusetts General Hospital Cancer Center, Boston, MA; University of Montreal Hospital Center, Montreal, QC, Canada; Carolina Urologic Research Center, Myrtle Beach, SC; Georges Pompidou European Hospital, Paris, France; Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Université Catholique de Louvain, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Urological Associates of Lancaster, Ltd., Lancaster, PA; Institut Gustave Roussy, University of Paris Sud, Villejuif, France
| |
Collapse
|
9
|
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379:39-46. [PMID: 22093187 PMCID: PMC3671878 DOI: 10.1016/s0140-6736(11)61226-9] [Citation(s) in RCA: 571] [Impact Index Per Article: 47.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Bone metastases are a major cause of morbidity and mortality in men with prostate cancer. Preclinical studies suggest that osteoclast inhibition might prevent bone metastases. We assessed denosumab, a fully human anti-RANKL monoclonal antibody, for prevention of bone metastasis or death in non-metastatic castration-resistant prostate cancer. METHODS In this phase 3, double-blind, randomised, placebo-controlled study, men with non-metastatic castration-resistant prostate cancer at high risk of bone metastasis (prostate-specific antigen [PSA] ≥8·0 μg/L or PSA doubling time ≤10·0 months, or both) were enrolled at 319 centres from 30 countries. Patients were randomly assigned (1:1) via an interactive voice response system to receive subcutaneous denosumab 120 mg or subcutaneous placebo every 4 weeks. Randomisation was stratified by PSA eligibility criteria and previous or ongoing chemotherapy for prostate cancer. Patients, investigators, and all people involved in study conduct were masked to treatment allocation. The primary endpoint was bone-metastasis-free survival, a composite endpoint determined by time to first occurrence of bone metastasis (symptomatic or asymptomatic) or death from any cause. Efficacy analysis was by intention to treat. The masked treatment phase of the trial has been completed. This trial was registered at ClinicalTrials.gov, number NCT00286091. FINDINGS 1432 patients were randomly assigned to treatment groups (716 denosumab, 716 placebo). Denosumab significantly increased bone-metastasis-free survival by a median of 4·2 months compared with placebo (median 29·5 [95% CI 25·4-33·3] vs 25·2 [22·2-29·5] months; hazard ratio [HR] 0·85, 95% CI 0·73-0·98, p=0·028). Denosumab also significantly delayed time to first bone metastasis (33·2 [95% CI 29·5-38·0] vs 29·5 [22·4-33·1] months; HR 0·84, 95% CI 0·71-0·98, p=0·032). Overall survival did not differ between groups (denosumab, 43·9 [95% CI 40·1-not estimable] months vs placebo, 44·8 [40·1-not estimable] months; HR 1·01, 95% CI 0·85-1·20, p=0·91). Rates of adverse events and serious adverse events were similar in both groups, except for osteonecrosis of the jaw and hypocalcaemia. 33 (5%) patients on denosumab developed osteonecrosis of the jaw versus none on placebo. Hypocalcaemia occurred in 12 (2%) patients on denosumab and two (<1%) on placebo. INTERPRETATION This large randomised study shows that targeting of the bone microenvironment can delay bone metastasis in men with prostate cancer. FUNDING Amgen Inc.
Collapse
Affiliation(s)
- Matthew R Smith
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ 2012; 15:712-23. [PMID: 22409231 DOI: 10.3111/13696998.2012.675380] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE With increasing healthcare resource constraints, it has become important to understand the incremental cost-effectiveness of new medicines. Subcutaneous denosumab is superior to intravenous zoledronic acid (ZA) for the prevention of skeletal-related events (SREs) in patients with advanced solid tumors and bone metastases. This study sought to determine the lifetime cost-effectiveness of denosumab vs ZA in this setting, from a US managed-care perspective. METHODS A lifetime Markov model was developed, with relative rate reductions in SREs for denosumab vs ZA derived from three pivotal Phase 3 trials involving patients with castration-resistant prostate cancer (CRPC), breast cancer, and non-small-cell lung cancer (NSCLC), and bone metastases. The real-world SRE rates in ZA-treated patients were derived from a large commercial database. SRE and treatment administration quality-adjusted life year (QALY) decrements were estimated with time-trade-off studies. SRE costs were estimated from a nationally representative commercial claims database. Drug, drug administration, and renal monitoring costs were included. Costs and QALYs were discounted at 3% annually. One-way and probabilistic sensitivity analyses were conducted. RESULTS Across tumor types, denosumab was associated with a reduced number of SREs, increased QALYs, and increased lifetime total costs vs ZA. The costs per QALY gained for denosumab vs ZA in CRPC, breast cancer, and NSCLC were $49,405, $78,915, and $67,931, respectively, commonly considered good value in the US. Costs per SRE avoided were $8567, $13,557, and $10,513, respectively. Results were sensitive to drug costs and SRE rates. LIMITATIONS Differences in pain severity and analgesic use favoring denosumab over ZA were not captured. Mortality was extrapolated from fitted generalized gamma function beyond the trial duration. CONCLUSION Denosumab is a cost-effective treatment option for the prevention of SREs in patients with advanced solid tumors and bone metastases compared to ZA. The overall value of denosumab is based on superior efficacy, favorable safety, and more efficient administration.
Collapse
Affiliation(s)
- Alison Stopeck
- University of Arizona Cancer Center, Tucson, AZ 85724-5024, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Goss PE, Barrios CH, Bell R, Finkelstein D, Iwata H, Martin M, Braun A, Ke C, Maniar T, Braun S, Dansey R, Coleman RE. OT1-01-03: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot1-01-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Bone is a common site of distant recurrence in women with early-stage breast cancer. Cancer cells are thought to stimulate osteoclast-mediated bone resorption, which releases growth factors and cytokines that promote tumor growth. RANK Ligand (RANKL) is the key mediator of osteoclast-induced bone destruction. In preclinical studies, RANKL inhibition reduced the incidence of bone and lung metastases, suppressed tumor progression, and prolonged survival of tumor-bearing mice. Effects were additive with hormonal, chemotherapy, or targeted therapies. Denosumab is a fully human monoclonal antibody against RANKL, approved in the U.S. for the prevention of skeletal-related events in patients with bone metastases from solid tumors. In patients with castrate-resistant prostate cancer, denosumab significantly improved bone metastasis-free survival (BMFS) compared to placebo. The D-CARE trial evaluates BMFS effects of denosumab in women with stage II or III breast cancer.
Methods: Women with node-positive or locally advanced (T3 or T4) disease, and known hormone and HER-2 receptor status are eligible. Standard-of-care adjuvant or neoadjuvant chemo-, endocrine, or HER-2 targeted therapy, alone or in combination must be planned with curative intent. Women with a prior history of breast cancer (other than ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS]) or distant metastasis, oral bisphosphonate (BP) use within 1 year or any intravenous BP use are excluded. Patients are randomized 1:1 to receive denosumab 120 mg or placebo subcutaneously monthly for 6 mos, then every 3 mos, for a total of 5 yrs treatment. All patients receive vitamin D (≥ 400 IU) and calcium (≥ 500 mg) supplements. Primary endpoint of this event-driven trial is BMFS. Secondary endpoints include disease-free (DFS) and overall survival. The study is powered for both, BMFS and DFS. Safety, quality of life assessments and biomarkers are additional endpoints. The trial, sponsored by Amgen Inc. and registered with the ClinicalTrials.gov identifier NCT01077154 began enrolling patients in June 2010. PG and DF are supported in part by the Avon Foundation, NY.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT1-01-03.
Collapse
Affiliation(s)
- PE Goss
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - CH Barrios
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - R Bell
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - D Finkelstein
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - H Iwata
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - M Martin
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - A Braun
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - C Ke
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - T Maniar
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - S Braun
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - R Dansey
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| | - RE Coleman
- 1Massachusetts General Hospital Cancer Center, Boston, MA; PUCRS School of Medicine, Porto Alegre RS, Brazil; Barwon Health, Geelong, Victoria, Australia; Aichi Cancer Center Hospital, Nagoya, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc, Thousand Oaks, CA; Amgen (Europe) GmbH, Zug, Switzerland; University of Sheffield, Sheffield, United Kingdom
| |
Collapse
|
12
|
Oudard S, Smith M, Karsh L, Egerdie B, Van Veldhuizen P, Gómez-Veiga F, Dearnaley D, Ye Z, Dansey R, Goessl C. 7003 ORAL Denosumab and Bone Metastasis-free Survival in Men With Castrate-resistant Prostate Cancer – Subgroup Analyses From an International, Double-blind, Randomized, Phase 3 Trial. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71954-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Reply to S.M. Sorscher et al. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.35.9182] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Luis Costa
- Hospital de Santa Maria, Lisboa, Portugal
| | | | - Vera Hirsh
- McGill University Health Centre, Montreal, Quebec, Canada
| | - Vania Hungria
- Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Reply to V. Fusco et al. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.35.2203] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Allan Lipton
- Penn State Milton S. Hershey Medical Center, Hershey, PA
| | - Jean-Jacques Body
- Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Katia Tonkin
- Cross Cancer Institute, Edmonton, Alberta, Canada
| | | | | | | | | | - María Viniegra
- Corporacion Medica de General San Martin, San Martin, Argentina
| | | | | | | | | | | |
Collapse
|
15
|
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Reply to M.S. Aapro. J Clin Oncol 2011. [DOI: 10.1200/jco.2010.34.1511] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Allan Lipton
- Penn State Milton S. Hershey Medical Center, Hershey, PA
| | - Jean-Jacques Body
- Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Katia Tonkin
- Cross Cancer Institute, Edmonton, Alberta, Canada
| | | | | | | | - María Viniegra
- Corporacion Medica de General San Martin, San Martin, Argentina
| | | | | | | | | | | |
Collapse
|
16
|
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813-22. [PMID: 21353695 PMCID: PMC3090685 DOI: 10.1016/s0140-6736(10)62344-6] [Citation(s) in RCA: 1328] [Impact Index Per Article: 102.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer. METHODS In this phase 3 study, men with castration-resistant prostate cancer and no previous exposure to intravenous bisphosphonate were enrolled from 342 centres in 39 countries. An interactive voice response system was used to assign patients (1:1 ratio), according to a computer-generated randomisation sequence, to receive 120 mg subcutaneous denosumab plus intravenous placebo, or 4 mg intravenous zoledronic acid plus subcutaneous placebo, every 4 weeks until the primary analysis cutoff date. Randomisation was stratified by previous skeletal-related event, prostate-specific antigen concentration, and chemotherapy for prostate cancer within 6 weeks before randomisation. Supplemental calcium and vitamin D were strongly recommended. Patients, study staff, and investigators were masked to treatment assignment. The primary endpoint was time to first on-study skeletal-related event (pathological fracture, radiation therapy, surgery to bone, or spinal cord compression), and was assessed for non-inferiority. The same outcome was further assessed for superiority as a secondary endpoint. Efficacy analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00321620, and has been completed. FINDINGS 1904 patients were randomised, of whom 950 assigned to denosumab and 951 assigned to receive zoledronic acid were eligible for the efficacy analysis. Median duration on study at primary analysis cutoff date was 12·2 months (IQR 5·9-18·5) for patients on denosumab and 11·2 months (IQR 5·6-17·4) for those on zoledronic acid. Median time to first on-study skeletal-related event was 20·7 months (95% CI 18·8-24·9) with denosumab compared with 17·1 months (15·0-19·4) with zoledronic acid (hazard ratio 0·82, 95% CI 0·71-0·95; p = 0·0002 for non-inferiority; p = 0·008 for superiority). Adverse events were recorded in 916 patients (97%) on denosumab and 918 patients (97%) on zoledronic acid, and serious adverse events were recorded in 594 patients (63%) on denosumab and 568 patients (60%) on zoledronic acid. More events of hypocalcaemia occurred in the denosumab group (121 [13%]) than in the zoledronic acid group (55 [6%]; p<0·0001). Osteonecrosis of the jaw occurred infrequently (22 [2%] vs 12 [1%]; p = 0·09). INTERPRETATION Denosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer. FUNDING Amgen.
Collapse
Affiliation(s)
- Karim Fizazi
- Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K. Estimating Minimally Important Differences for the Worst Pain Rating of the Brief Pain Inventory–Short Form. ACTA ACUST UNITED AC 2011; 9:72-8. [DOI: 10.1016/j.suponc.2010.12.004] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
18
|
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011. [PMID: 21343556 DOI: 10.1200/jco.2010.31.3304jco.2010.31.3304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
PURPOSE This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myeloma. PATIENTS AND METHODS Eligible patients were randomly assigned in a double-blind, double-dummy design to receive monthly subcutaneous denosumab 120 mg (n = 886) or intravenous ZA 4 mg (dose adjusted for renal impairment; n = 890). Daily supplemental calcium and vitamin D were strongly recommended. The primary end point was time to first on-study SRE (pathologic fracture, radiation or surgery to bone, or spinal cord compression). RESULTS Denosumab was noninferior to ZA in delaying time to first on-study SRE (hazard ratio, 0.84; 95% CI, 0.71 to 0.98; P = .0007). Although directionally favorable, denosumab was not statistically superior to ZA in delaying time to first on-study SRE (P = .03 unadjusted; P = .06 adjusted for multiplicity) or time to first-and-subsequent (multiple) SRE (rate ratio, 0.90; 95% CI, 0.77 to 1.04; P = .14). Overall survival and disease progression were similar between groups. Hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred at similarly low rates in both groups. Acute-phase reactions after the first dose occurred more frequently with ZA, as did renal adverse events and elevations in serum creatinine based on National Cancer Institute Common Toxicity Criteria for Adverse Events grading. CONCLUSION Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma. Denosumab represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Collapse
Affiliation(s)
- David H Henry
- Joan Karnell Cancer Center, Philadelphia, PA 19106, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125-32. [PMID: 21343556 DOI: 10.1200/jco.2010.31.3304] [Citation(s) in RCA: 810] [Impact Index Per Article: 62.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
PURPOSE This study compared denosumab, a fully human monoclonal anti-receptor activator of nuclear factor kappa-B ligand antibody, with zoledronic acid (ZA) for delaying or preventing skeletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myeloma. PATIENTS AND METHODS Eligible patients were randomly assigned in a double-blind, double-dummy design to receive monthly subcutaneous denosumab 120 mg (n = 886) or intravenous ZA 4 mg (dose adjusted for renal impairment; n = 890). Daily supplemental calcium and vitamin D were strongly recommended. The primary end point was time to first on-study SRE (pathologic fracture, radiation or surgery to bone, or spinal cord compression). RESULTS Denosumab was noninferior to ZA in delaying time to first on-study SRE (hazard ratio, 0.84; 95% CI, 0.71 to 0.98; P = .0007). Although directionally favorable, denosumab was not statistically superior to ZA in delaying time to first on-study SRE (P = .03 unadjusted; P = .06 adjusted for multiplicity) or time to first-and-subsequent (multiple) SRE (rate ratio, 0.90; 95% CI, 0.77 to 1.04; P = .14). Overall survival and disease progression were similar between groups. Hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred at similarly low rates in both groups. Acute-phase reactions after the first dose occurred more frequently with ZA, as did renal adverse events and elevations in serum creatinine based on National Cancer Institute Common Toxicity Criteria for Adverse Events grading. CONCLUSION Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma. Denosumab represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Collapse
Affiliation(s)
- David H Henry
- Joan Karnell Cancer Center, Philadelphia, PA 19106, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Fallowfield L, Patrick D, Body JJ, Lipton A, Tonkin KS, Qian Y, Zhao Y, Jiang Q, Braun A, Dansey R, Chung K. Abstract P1-13-05: The Effect of Treatment with Denosumab or Zoledronic Acid on Health-Related Quality of Life in Patients with Metastatic Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-13-05] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients with breast cancer and bone metastases often experience skeletal-related events (SREs) and pain, which may impact health-related quality of life (HRQoL). Denosumab is a fully human monoclonal antibody against RANKL shown to be superior in delaying/preventing SREs and more effective in delaying moderate or severe pain in patients with advanced breast cancer compared with zoledronic acid (ZA). Previously reported results from this study population showed that both denosumab and ZA patients showed improvement or maintenance in HRQoL relative to baseline (BL), and a greater proportion of denosumab-treated patients had a clinically meaningful improvement in HRQoL. We now describe the effect of denosumab and ZA treatment on HRQoL among patients with varying degrees of pain at BL.
Methods: Enrolled patients received subcutaneous (SC) denosumab 120 mg or intravenous (IV) ZA 4 mg every 4 weeks in a double-blind, double-dummy fashion. Pain was evaluated using the Brief Pain Inventory — Short Form (BPI). Patients were divided into 2 subgroups based on the level of pain reported at BL: no/mild pain or moderate/severe pain. Patients completed the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at BL, day 8, and before each monthly visit to assess overall HRQoL. Higher scores (range 0 to 108) represent better HRQoL. Improvement, maintenance, and worsening of HRQoL were assessed through month 18, when 30% of patients had dropped out due to death, disease progression, or withdrawal of consent. A change of ≥5 points (increase or decrease) in the FACT-G total score was considered a meaningful improvement.
Results: Among patients who reported no/mild pain at baseline, more denosumab-treated patients had a ≥5-point increase in their FACT-G score from month 4 onwards. Over the 18 month period, an average of 4.1% more (range: −0.6% to 9.3%) denosumab-treated patients experienced meaningful improvement in HRQoL than ZA-treated patients. There were also fewer denosumab-treated patients experiencing ≥5-point decrease in HRQoL over 18 months (average of 2.4% fewer [range:-4.4% to 6.3% fewer]). Similar patterns were also noted for patients with moderate/severe pain at baseline. An average of 3.0% more (range:-1.7% to 7.9%) denosumab-treated patients had ≥5-point increase in FACT-G scores compared with ZA-treated patients over 18 months. A lower proportion of denosumab-treated patients (3.5% fewer [range: −1.1% to 11.5% fewer]) than ZA-treated patients had a decrease ≥5-points in their FACT-G score over 18 months.
Conclusion: In patients with breast cancer and bone metastases, a greater proportion treated with denosumab than ZA had a meaningful improvement in HRQoL regardless of their pain level at BL.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-13-05.
Collapse
Affiliation(s)
- L Fallowfield
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - D Patrick
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - J-J Body
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - A Lipton
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - KS Tonkin
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - Y Qian
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - Y Zhao
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - Q Jiang
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - A Braun
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - R Dansey
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| | - K. Chung
- University of Sussex, Brighton, United Kingdom; University of Washington, Seattle; CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium; Penn State Milton S. Hershey Medical Center, Hershey, PA; Cross Cancer Institute, Edmonton, AB, Canada; Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
21
|
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28:5132-9. [PMID: 21060033 DOI: 10.1200/jco.2010.29.7101] [Citation(s) in RCA: 1018] [Impact Index Per Article: 72.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE This randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor κ B (RANK) ligand, with zoledronic acid in delaying or preventing skeletal-related events (SREs) in patients with breast cancer with bone metastases. PATIENTS AND METHODS Patients were randomly assigned to receive either subcutaneous denosumab 120 mg and intravenous placebo (n = 1,026) or intravenous zoledronic acid 4 mg adjusted for creatinine clearance and subcutaneous placebo (n = 1,020) every 4 weeks. All patients were strongly recommended to take daily calcium and vitamin D supplements. The primary end point was time to first on-study SRE (defined as pathologic fracture, radiation or surgery to bone, or spinal cord compression). RESULTS Denosumab was superior to zoledronic acid in delaying time to first on-study SRE (hazard ratio, 0.82; 95% CI, 0.71 to 0.95; P = .01 superiority) and time to first and subsequent (multiple) on-study SREs (rate ratio, 0.77; 95% CI, 0.66 to 0.89; P = .001). Reduction in bone turnover markers was greater with denosumab. Overall survival, disease progression, and rates of adverse events (AEs) and serious AEs were similar between groups. An excess of renal AEs and acute-phase reactions occurred with zoledronic acid; hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred infrequently (2.0%, denosumab; 1.4%, zoledronic acid; P = .39). CONCLUSION Denosumab was superior to zoledronic acid in delaying or preventing SREs in patients with breast cancer metastatic to bone and was generally well tolerated. With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
Collapse
|
22
|
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010. [PMID: 21060033 DOI: 10.1200/jco.2010.29.7101jco.2010.29.7101] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
PURPOSE This randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor κ B (RANK) ligand, with zoledronic acid in delaying or preventing skeletal-related events (SREs) in patients with breast cancer with bone metastases. PATIENTS AND METHODS Patients were randomly assigned to receive either subcutaneous denosumab 120 mg and intravenous placebo (n = 1,026) or intravenous zoledronic acid 4 mg adjusted for creatinine clearance and subcutaneous placebo (n = 1,020) every 4 weeks. All patients were strongly recommended to take daily calcium and vitamin D supplements. The primary end point was time to first on-study SRE (defined as pathologic fracture, radiation or surgery to bone, or spinal cord compression). RESULTS Denosumab was superior to zoledronic acid in delaying time to first on-study SRE (hazard ratio, 0.82; 95% CI, 0.71 to 0.95; P = .01 superiority) and time to first and subsequent (multiple) on-study SREs (rate ratio, 0.77; 95% CI, 0.66 to 0.89; P = .001). Reduction in bone turnover markers was greater with denosumab. Overall survival, disease progression, and rates of adverse events (AEs) and serious AEs were similar between groups. An excess of renal AEs and acute-phase reactions occurred with zoledronic acid; hypocalcemia occurred more frequently with denosumab. Osteonecrosis of the jaw occurred infrequently (2.0%, denosumab; 1.4%, zoledronic acid; P = .39). CONCLUSION Denosumab was superior to zoledronic acid in delaying or preventing SREs in patients with breast cancer metastatic to bone and was generally well tolerated. With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
Collapse
|
23
|
Kool B, Jackson C, Civil I, Dansey R, Ameratunga S. Linking trauma registry injury data with national injury compensation data - opportunities for public health action in New Zealand. Inj Prev 2010. [DOI: 10.1136/ip.2010.029215.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Wang J, Jun S, Yeh H, Dansey R. 20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72055-5] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
25
|
Smith M, Egerdie B, Sieber P, Tammela T, Saad F, Ke C, Leder B, Dansey R, Goessl C. 7005 Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71383-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
26
|
Bezwoda WR, Dansey R. High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease. Leuk Lymphoma 2009; 1:71-5. [DOI: 10.3109/10428198909042462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
27
|
Smith MR, Ellis G, Saad F, Tammela T, Bone H, Egerdie B, Ke C, Jun S, Dansey R, Goessl C. Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9520] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9520 Background: Hormone ablation therapies, including adjuvant aromatase inhibitor (AI) therapy and androgen deprivation therapy (ADT), improve recurrence-free survival in patients (pts) with BC and PC, respectively. However, these treatments increase bone resorption, leading to bone loss and fractures. RANKL is a key mediator of osteoclast-mediated bone resorption. In this 24 month (mo) comparison, we investigated the effects of denosumab, a fully human monoclonal antibody against RANKL, on preserving BMD across both populations. Methods: Two trials were conducted: a 24-mo BC study and a 36-mo PC study. Postmenopausal women with low BMD receiving AI therapy for nonmetastatic BC and men receiving ADT for nonmetastatic PC (with low BMD or history of osteoporotic fracture if < 70 yrs) were randomized to receive placebo or denosumab 60mg subcutaneously every 6 mos. All pts in both studies were prescribed calcium and vitamin D supplements. The primary endpoint was % change from baseline in lumbar spine (LS) BMD at 12 mos for the BC study and at 24 mos for the PC study. Herein, we present changes in BMD at 24 mos at LS, total hip (TH), and 1/3 radius from both studies. Power calculations were based on enrollment of at least 208 patients in the BC study (for primary endpoint only) and 1226 in the PC study (for primary and key secondary endpoints). The actual numbers randomized were 252 and 1468, respectively. Results: Denosumab increased BMD of the LS, TH, and 1/3 radius compared with placebo at 24 mos in both pt populations ( Table ). In both studies, differences between denosumab and placebo at each skeletal site were consistent, and the effects of denosumab were statistically significantly different from placebo as early as 1 month at the LS in both studies. The overall safety profile was similar to placebo in each study. Conclusions: Denosumab consistently increased BMD at all 3 skeletal sites compared with placebo in both women with BC undergoing AI therapy and in men with PC undergoing ADT. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- M. R. Smith
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - G. Ellis
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - F. Saad
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - T. Tammela
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - H. Bone
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - B. Egerdie
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - C. Ke
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - S. Jun
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - R. Dansey
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - C. Goessl
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| |
Collapse
|
28
|
Egerdie B, Smith MR, Tammela TLJ, Saad F, Ke C, Goessl C, Dansey R. A RESPONDER ANALYSIS OF THE EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY IN MEN WITH PROSTATE CANCER RECEIVING ANDROGEN DEPRIVATION THERAPY. J Urol 2009. [DOI: 10.1016/s0022-5347(09)61717-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 2008; 8:195. [PMID: 18616811 PMCID: PMC2483721 DOI: 10.1186/1471-2407-8-195] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2007] [Accepted: 07/10/2008] [Indexed: 11/29/2022] Open
Abstract
Background Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in serious, potentially life-threatening, infection. This randomized, double-blind, phase 2 clinical trial compared the efficacy and tolerability of pegfilgrastim with filgrastim for assisting neutrophil recovery following induction and consolidation chemotherapy for de novo AML in patients with low-to-intermediate risk cytogenetics. Methods Patients (n = 84) received one or two courses of standard induction chemotherapy (idarubicin + cytarabine), followed by one course of consolidation therapy (high-dose cytarabine) if complete remission was achieved. They were randomized to receive either single-dose pegfilgrastim 6 mg or daily filgrastim 5 μg/kg, beginning 24 hours after induction and consolidation chemotherapy. Results The median time to recovery from severe neutropenia was 22.0 days for both pegfilgrastim (n = 42) and filgrastim (n = 41) groups during Induction 1 (difference 0.0 days; 95% CI: -1.9 to 1.9). During Consolidation, recovery occurred after a median of 17.0 days for pegfilgrastim versus 16.5 days for filgrastim (difference 0.5 days; 95% CI: -1.1 to 2.1). Therapeutic pegfilgrastim serum concentrations were maintained throughout neutropenia. Pegfilgrastim was well tolerated, with an adverse event profile similar to that of filgrastim. Conclusion These data suggest no clinically meaningful difference between a single dose of pegfilgrastim and multiple daily doses of filgrastim for shortening the duration of severe neutropenia following chemotherapy in de novo AML patients with low-to-intermediate risk cytogenetics. Trial registration Clinicaltrials.gov NCT00114764
Collapse
Affiliation(s)
- Jorge Sierra
- Division of Clinical Hematology, Hospital de Santa Creu i Sant Pau, Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Peres E, Wood GW, Poulik J, Baynes R, Sood S, Abidi MH, Klein J, Bhambhani K, Dansey R, Abella E. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 2008; 39:151-6. [PMID: 18991194 DOI: 10.1055/s-0028-1093333] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Pediatric patients with recurrent brain tumors have a poor prognosis and limited therapeutic options. We investigated the use of high-dose chemotherapy with adoptive immunotherapy for recurrent brain tumors. Three pediatric patients with recurrent brain tumors received high-dose chemotherapy. This was followed by adoptive transfer of ex-vivo expanded T-cells. The T-cells were generated from peripheral blood after immunization with autologous cancer cells. The objectives of this study included (1) establishing the safety and feasibility of this potential treatment, (2) measuring changes in immune response after high-dose chemotherapy and adoptive immunotherapy, and (3) determining whether adoptive immunotherapy would be able to translate into a clinical response. Immune function was tested in all patients at the time of enrollment into the study. Humoral responses to recall antigens delayed-type hypersensitivity (DTH) were intact in all patients. After immunizing patients with autologous cancer cells, peripheral blood lymphocytes were harvested and activated with anti-CD3, expanded in-vitro, and infused post-autologous transplant. Patients received at least three doses of the vaccine, each consisting of an intradermal administration near a draining lymph node at biweekly intervals. Toxicity was limited and well tolerated in all patients. All three patients showed a tumor-specific immune response by serial imaging. Responses were durable at 16, 23, and 48 months, respectively.
Collapse
Affiliation(s)
- E Peres
- Dept. of Hematology & Oncology, Karmanos Cancer Institute, Div. of Pediatric Hematology-Oncology, and Dept. of Pediatric Neurosurgery, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, Michigan, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Peres E, Abidi MH, Mellon-Reppen S, Klein J, Braun T, Abella E, Dansey R. Reduced intensity transplantation for metastatic renal cell cancer with 2-year follow-up. J Immunother 2007; 30:562-6. [PMID: 17589297 DOI: 10.1097/cji.0b013e318046f380] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Metastatic renal cell carcinoma (RCC) is a disease that is resistant to conventional systemic therapy. Nonmyeloablative allogeneic stem cell transplant has activity in patients with metastatic RCC. This approach has been used in related donor transplantation but there are limited data on outcomes in the setting of unrelated donor (URD) transplantation. This phase II trial assessed the efficacy, safety, and responses in 16 patients, 10 related and 6 URD transplants after a reduced intensity conditioning regimen and stem cell transplant as a treatment for metastatic RCC. Sixteen patients received a conditioning consisting of either fludarabine, cyclophosphamide (n=11) or fludarabine, total body irradiation (n=5) followed by transplantation from an HLA-matched sibling donor or a unrelated HLA-donor. Cyclosporine and mycophenolate mofetil were administered as posttransplant immunosuppression. Patients were monitored for engraftment by short tandem repeat for myeloid and lymphoid lineages and clinical response was assessed by serial imaging. All patients achieved donor chimerism, 7 patients developed acute, grades 2 to 3, graft-versus-host disease. Chronic graft-versus-host disease occurred in 6 patients and transplant-related mortality was 12%. Of the 10 related donors, 1 obtained a complete response, 3 had a partial response, and 3 had stable disease. In the 6 patients who underwent URD transplant, 1 obtained a complete response and 1 patient had stable disease. These results suggest that similar outcomes are possible where either related or URD were used as the stem cell source in reduced intensity stem cell transplant for metastatic RCC.
Collapse
Affiliation(s)
- Edward Peres
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Peterson MC, Jang G, Kim W, Gurrola E, Kinsey A, Dansey R. Selection of a phase 3 dose regimen for denosumab based on pharmacokinetic (PK), pharmacodynamic (PD), and safety data from multiple subcutaneous (SC) dosing regimens in breast cancer patients (pts) with bone metastases (BM). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3086] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3086 Background: Receptor activator of NF-κB ligand (RANKL) is essential for osteoclast formation, function, and survival. PK and PD of denosumab (AMG 162), a fully human monoclonal IgG2 antibody to RANKL, from a randomized, double-blind, active-controlled, multidose study in breast cancer pts with BM were evaluated and modeled to assist in dose selection for the pivotal phase 3 study. Methods: Five dosing cohorts (∼40/cohort) received 30-, 120-, or 180-mg denosumab SC Q4W; 60- or 180-mg denosumab SC Q12W. Data through 12 weeks were used for PK/PD modeling and dose decisions. Validated methods were used to quantify all serum and urine analytes. The bone resorption marker uNTx (reported as uNTx/Cr ratio) was used as the PD endpoint, and population PK/PD model parameters were estimated using nonlinear mixed effects modeling methods (NONMEM). A combination of PK/PD trial simulation (TS), clinical chemistries, and safety profiles was utilized for phase 3 dose selection. Results: Exposure to denosumab increased approximately dose-proportionally for both the Q4W and Q12W schedules, and accumulation (3rd vs 1st Q4W dose) ranged from 2.37- to 2.56-fold. The population typical half-maximal inhibitory concentration (IC50) for denosumab to affect uNTx and the typical maximum suppression were estimated to be 12.2 ng/mL and 77.8%, respectively. While denosumab in all cohorts caused rapid and sustained suppression of uNTx from baseline (>60%), TS showed that for a dose of 120 mg Q4W, 97% of subjects would be expected to attain denosumab serum concentrations above their individual IC90 at steady state. TS did not suggest that higher doses (180 mg Q4W) would result in further uNTx suppression, and more asymptomatic decreases in calcium were noted in pts dosed above 120 mg Q4W. Conclusions: The PK and PD of denosumab in pts with BM are consistent with those in other pt populations and demonstrate rapid and substantial suppression of uNTx. Population PK/PD analysis and TS suggests a dose of 120mg Q4W is appropriate for use in a phase 3 program in this study population. [Table: see text]
Collapse
Affiliation(s)
| | - G. Jang
- Amgen, Inc., Thousand Oaks, CA
| | - W. Kim
- Amgen, Inc., Thousand Oaks, CA
| | | | | | | |
Collapse
|
33
|
Peres E, Savasan S, Klein J, Abidi M, Dansey R, Abella E. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. J Clin Microbiol 2005; 43:3540-3. [PMID: 16000501 PMCID: PMC1169101 DOI: 10.1128/jcm.43.7.3540-3543.2005] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (EBV-LPD) following bone marrow transplantation can be fatal. The major risk factors for the development of EBV-LPD are ex vivo T-cell depletion or in vivo T-cell depletion with either antithymocyte globulin (ATG) or monoclonal anti-T-cell antibodies. Between March 1999 and January 2001, a total of 23 transplants with ATG of equine source (20 transplants) and ATG of rabbit source (3 transplants) used as part of the preparatory regimen were performed at the Barbara Ann Karmanos Cancer Institute in Detroit, Mich. The three patients who received rabbit ATG developed EBV-LPD between 60 and 90 days following bone marrow transplantation. However, there were no cases of EBV-LPD in the equine group. Treatment given in these cases consisted of tapering immunosuppression, antiviral therapy, unprocessed donor lymphocyte infusion, mobilized peripheral blood progenitor cell rescue infusion (one patient), and chemotherapy (one patient). All three patients died of complications from EBV-LPD. The association of rabbit ATG with the development of EBV-LPD suggests that patients receiving rabbit ATG as part of their preparatory regimens require close monitoring of the EBV viral load and possible early intervention with antiviral therapy.
Collapse
Affiliation(s)
- E Peres
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute, Harper Hospital of Michigan, 4100 John R, Detroit, MI 48201, USA.
| | | | | | | | | | | |
Collapse
|
34
|
Abstract
A 2-yr and 9-month-old female patient with neurofibromatosis type-1 presented with hepatomegaly, anemia, thrombocytopenia, and croupy cough and diagnosed with xanthogranuloma disseminatum (XD). She failed chemotherapy consisting of steroids, 6-mercaptopurine and methotrexate. A partial response to HLH-94 therapy that included etoposide and cyclosporine A was initially observed. However, she continued to have significant organ dysfunction without further improvement at 6 months of therapy. She then received matched unrelated donor bone marrow transplantation (BMT) following carmustine, etoposide, cytarabine and melphelan conditioning with complete resolution of symptoms. BMT is an option in therapy-resistant, life threatening XD cases.
Collapse
Affiliation(s)
- Süreyya Savaşan
- Division of Hematology/Oncology, Children's Hospital of Michigan, MI 48201, USA.
| | | | | | | | | |
Collapse
|
35
|
Ozer H, Mirtsching B, Rader M, Ding B, Dansey R. Impact of 1st and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy: Preliminary results of FIRST, a prospective community-based study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8118] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Ozer
- Univ of Oklahoma Cancer Ctr, Oklahoma City, OK; Ctr for Oncology Research & Treatment, Dallas, TX; Hematology-Oncology of Rockland, New City, NY; Amgen Inc., Thousand Oaks, CA
| | - B. Mirtsching
- Univ of Oklahoma Cancer Ctr, Oklahoma City, OK; Ctr for Oncology Research & Treatment, Dallas, TX; Hematology-Oncology of Rockland, New City, NY; Amgen Inc., Thousand Oaks, CA
| | - M. Rader
- Univ of Oklahoma Cancer Ctr, Oklahoma City, OK; Ctr for Oncology Research & Treatment, Dallas, TX; Hematology-Oncology of Rockland, New City, NY; Amgen Inc., Thousand Oaks, CA
| | - B. Ding
- Univ of Oklahoma Cancer Ctr, Oklahoma City, OK; Ctr for Oncology Research & Treatment, Dallas, TX; Hematology-Oncology of Rockland, New City, NY; Amgen Inc., Thousand Oaks, CA
| | - R. Dansey
- Univ of Oklahoma Cancer Ctr, Oklahoma City, OK; Ctr for Oncology Research & Treatment, Dallas, TX; Hematology-Oncology of Rockland, New City, NY; Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
36
|
Campos LT, Folbe M, Meza L, Charu V, Dansey R, Xie F. Frequency of neutropenia-related events during chemotherapy and the use of pegfilgrastim and filgrastim in community practice: Results of the ACCEPT study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8115] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. T. Campos
- Oncology Consultants, PA, Houston, TX; Private Practice, Troy, MI; Southwest Oncology Assoc, Ltd, Lafayette, LA; Pacific Cancer Medcl Ctr, Anaheim, CA; Amgen Inc., Thousand Oaks, CA
| | - M. Folbe
- Oncology Consultants, PA, Houston, TX; Private Practice, Troy, MI; Southwest Oncology Assoc, Ltd, Lafayette, LA; Pacific Cancer Medcl Ctr, Anaheim, CA; Amgen Inc., Thousand Oaks, CA
| | - L. Meza
- Oncology Consultants, PA, Houston, TX; Private Practice, Troy, MI; Southwest Oncology Assoc, Ltd, Lafayette, LA; Pacific Cancer Medcl Ctr, Anaheim, CA; Amgen Inc., Thousand Oaks, CA
| | - V. Charu
- Oncology Consultants, PA, Houston, TX; Private Practice, Troy, MI; Southwest Oncology Assoc, Ltd, Lafayette, LA; Pacific Cancer Medcl Ctr, Anaheim, CA; Amgen Inc., Thousand Oaks, CA
| | - R. Dansey
- Oncology Consultants, PA, Houston, TX; Private Practice, Troy, MI; Southwest Oncology Assoc, Ltd, Lafayette, LA; Pacific Cancer Medcl Ctr, Anaheim, CA; Amgen Inc., Thousand Oaks, CA
| | - F. Xie
- Oncology Consultants, PA, Houston, TX; Private Practice, Troy, MI; Southwest Oncology Assoc, Ltd, Lafayette, LA; Pacific Cancer Medcl Ctr, Anaheim, CA; Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
37
|
Smith F, Kandahari M, Tomita D, Green J, Dansey R, Crawford J. Neutropenia and anxiety in advanced non-small cell lung cancer (NSCLC) patients: initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenia complications. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8173] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Smith
- Sibley Memorial Hosp, Washington, DC; Fairfax Hosp Cancer Ctr, Fairfax, VA; Amgen Inc., Thousand Oaks, CA; Duke Univ Medcl Ctr, Durham, NC
| | - M. Kandahari
- Sibley Memorial Hosp, Washington, DC; Fairfax Hosp Cancer Ctr, Fairfax, VA; Amgen Inc., Thousand Oaks, CA; Duke Univ Medcl Ctr, Durham, NC
| | - D. Tomita
- Sibley Memorial Hosp, Washington, DC; Fairfax Hosp Cancer Ctr, Fairfax, VA; Amgen Inc., Thousand Oaks, CA; Duke Univ Medcl Ctr, Durham, NC
| | - J. Green
- Sibley Memorial Hosp, Washington, DC; Fairfax Hosp Cancer Ctr, Fairfax, VA; Amgen Inc., Thousand Oaks, CA; Duke Univ Medcl Ctr, Durham, NC
| | - R. Dansey
- Sibley Memorial Hosp, Washington, DC; Fairfax Hosp Cancer Ctr, Fairfax, VA; Amgen Inc., Thousand Oaks, CA; Duke Univ Medcl Ctr, Durham, NC
| | - J. Crawford
- Sibley Memorial Hosp, Washington, DC; Fairfax Hosp Cancer Ctr, Fairfax, VA; Amgen Inc., Thousand Oaks, CA; Duke Univ Medcl Ctr, Durham, NC
| |
Collapse
|
38
|
Balducci L, Tam J, Al-Halawani H, Shahin S, Green J, Dansey R, Ershler W. A large study of the older cancer patient in the community setting: Initial report of a randomized controlled trial using pegfilgrastim to reduce neutropenic complications. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8111] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Balducci
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Geriatric Oncology Consortium, Baltimore, MD; Cabrini Ctr for Cancer Care, Alexandria, LA; Amgen Inc., Thousand Oaks, CA; Inst for Advanced Studies in Aging, Washington, DC
| | - J. Tam
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Geriatric Oncology Consortium, Baltimore, MD; Cabrini Ctr for Cancer Care, Alexandria, LA; Amgen Inc., Thousand Oaks, CA; Inst for Advanced Studies in Aging, Washington, DC
| | - H. Al-Halawani
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Geriatric Oncology Consortium, Baltimore, MD; Cabrini Ctr for Cancer Care, Alexandria, LA; Amgen Inc., Thousand Oaks, CA; Inst for Advanced Studies in Aging, Washington, DC
| | - S. Shahin
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Geriatric Oncology Consortium, Baltimore, MD; Cabrini Ctr for Cancer Care, Alexandria, LA; Amgen Inc., Thousand Oaks, CA; Inst for Advanced Studies in Aging, Washington, DC
| | - J. Green
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Geriatric Oncology Consortium, Baltimore, MD; Cabrini Ctr for Cancer Care, Alexandria, LA; Amgen Inc., Thousand Oaks, CA; Inst for Advanced Studies in Aging, Washington, DC
| | - R. Dansey
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Geriatric Oncology Consortium, Baltimore, MD; Cabrini Ctr for Cancer Care, Alexandria, LA; Amgen Inc., Thousand Oaks, CA; Inst for Advanced Studies in Aging, Washington, DC
| | - W. Ershler
- H Lee Moffitt Cancer Ctr & Rsrch Inst, Tampa, FL; Geriatric Oncology Consortium, Baltimore, MD; Cabrini Ctr for Cancer Care, Alexandria, LA; Amgen Inc., Thousand Oaks, CA; Inst for Advanced Studies in Aging, Washington, DC
| |
Collapse
|
39
|
Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Gumma MM, Milan N, Smith DW, Heilbrun LK, Klein J. Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Bone Marrow Transplant 2005; 35:1071-7. [PMID: 15821771 DOI: 10.1038/sj.bmt.1704952] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Few attempts have been made to examine the feasibility of safely administering low-molecular-weight-heparins (LMWHs) in the presence of concurrent thrombocytopenia. We retrospectively investigated the safety of low-dose LMWH in BMT patients, a population at risk of bleeding. In total, 26 patients received at least one dose of low-dose enoxaparin (ie <1 mg/kg/day) during thrombocytopenia. s.c. enoxaparin 40 mg once daily was given in 85% of the cohort. The mean number of platelet days <55 x 10(9) and <20 x 10(9)/l were 16.5 days (95% CI=8.04-24.96) and 4.14 days (95% CI=2.35-5.93), respectively. The mean number of low-dose enoxaparin administration days when platelet <55 x 10(9) and 20 x 10(9)/l were 9.89 days (95% CI=3.26-16.53) and 2.25 days (95% CI=0.57-3.93), respectively. Minor bleeding occurred in four patients (15%) whereas major episodes developed in two patients (8%). The latter two events occurred during the transition between full therapeutic (ie 1.5-2 mg/kg/day) and low-dose enoxaparin close to the onset of thrombocytopenia. The present case series, along with the discussed literature, descriptively suggests that low-dose enoxaparin may be safely administered at a platelet count in the range of 20 and 55 x 10(9)/l in BMT patients who weigh >55 kg.
Collapse
Affiliation(s)
- R B Ibrahim
- Department of Pharmacy, Karmanos Cancer Institute/Harper University Hospital/The Detroit Medical Center, 3990 John R., Detroit, MI 48201-2020, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Klein J. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. Ann Pharmacother 2004; 38:1053-9. [PMID: 15113990 DOI: 10.1345/aph.1d235] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE To describe the evidence assessing the use of anti-thrombin III (AT-III) in the management of toxicity associated with hematopoietic stem-cell transplantation (HSCT)-conditioning regimens. DATA SOURCES Clinical literature was accessed through conference proceedings, EMBASE, the Cochrane database, and MEDLINE (1966-December 2003). STUDY SELECTION AND DATA EXTRACTION Case reports, small case series, case-control and cohort studies, and randomized controlled trials of AT-III in HSCT were evaluated. Publications examining AT-III use in the non-HSCT setting were also explored. Key search terms included AT-III, transplantation, and veno-occlusive disease (VOD). DATA SYNTHESIS Severe VOD and ensuing multiple organ dysfunction is associated with high mortality in HSCT. A low AT-III level has been shown to correlate with the development of organ dysfunction. Phase II trials, case series, and one small, randomized, placebo-controlled study suggest a benefit when AT-III therapy is instituted early in the course of VOD/multiple organ dysfunction syndrome. In all of these reports, AT-III use was devoid of adverse events. CONCLUSIONS Although further studies are needed to ascertain the optimal target level, method, and duration of administration, AT-III is still a viable alternative for the treatment of severe VOD and ensuing multiple organ dysfunction.
Collapse
Affiliation(s)
- Rami B Ibrahim
- Karmanos Cancer Institute, Harper University Hospital, The Detroit Medical Center, 3990 John R, Detroit, MI 48201-2020, USA.
| | | | | | | | | | | |
Collapse
|
41
|
Jones RB, Stockerl-Goldstein KE, Klein J, Murphy J, Blume KG, Dansey R, Martinez C, Matthes S, Nieto Y. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. Biol Blood Marrow Transplant 2004; 10:276-82. [PMID: 15077226 DOI: 10.1016/j.bbmt.2004.01.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We conducted a randomized, double blind, placebo-controlled multi-institutional trial to assess the ability of amifostine to protect patients against acute lung injury associated with cyclophosphamide/cisplatin/carmustine (BCNU) (STAMP I), a BCNU-containing high dose chemotherapy regimen used with hematopoietic cell transplantation. Amifostine was administered in a dose of 740 mg/m(2) for 2 doses preceding administration of BCNU, the presumed pulmonary-toxic component of the regimen. The trial was stopped after 79 patients were randomized and a planned interim analysis demonstrated that it was unlikely that pulmonary cytoprotection would be detected with further accrual. We conclude that amifostine, used in the dose and schedule we tested, does not reduce the incidence of acute lung injury produced by STAMP I. Further, we suggest that amifostine use with BCNU in other contexts and with clinically achievable doses is unlikely to protect the lung from BCNU-associated acute injury.
Collapse
Affiliation(s)
- Roy B Jones
- Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Mellon-Reppen S, Dansey R, Abella E, Nehlsen-Cannarella S, Abidi M. Comparison of lymphoid and myeloid engraftment rates in patients receiving fludarabine/TBI or fludarabine/cyclophosphamide for non-myeloablative allogeneic transplantation. Biol Blood Marrow Transplant 2004. [DOI: 10.1016/j.bbmt.2003.12.251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
|
44
|
Nash RA, Dansey R, Storek J, Georges GE, Bowen JD, Holmberg LA, Kraft GH, Mayes MD, McDonagh KT, Chen CS, Dipersio J, Lemaistre CF, Pavletic S, Sullivan KM, Sunderhaus J, Furst DE, McSweeney PA. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9:583-91. [PMID: 14506660 PMCID: PMC2956744 DOI: 10.1016/s1083-8791(03)00228-3] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
High-dose immunosuppressive therapy followed by autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated for the control of severe autoimmune diseases. The addition of antithymocyte globulin (ATG) to high-dose chemoradiotherapy in the high-dose immunosuppressive therapy regimen and CD34 selection of the autologous graft may induce a higher degree of immunosuppression compared with conventional autologous HSCT for malignant diseases. Patients may be at higher risk of transplant-related complications secondary to the immunosuppressed state, including Epstein-Barr virus (EBV)-associated posttransplantation lymphoproliferative disorder (PTLD), but this is an unusual complication after autologous HSCT. Fifty-six patients (median age, 42 years; range, 23-61 years) with either multiple sclerosis (n = 26) or systemic sclerosis (n = 30) have been treated. The median follow-up has been 24 months (range, 2-60 months). Two patients (multiple sclerosis, n = 1; systemic sclerosis, n = 1) had significant reactivations of herpesvirus infections early after HSCT and then developed aggressive EBV-PTLD and died on days +53 and +64. Multiorgan clonal B-cell infiltrates that were EBV positive by molecular studies or immunohistology were identified at both autopsies. Both patients had positive screening skin tests for equine ATG (Atgam) and had been converted to rabbit ATG (Thymoglobulin) from the first dose. Of the other 54 patients, 2 of whom had partial courses of rabbit ATG because of a reaction to the intravenous infusion of equine ATG, only 1 patient had a significant clinical reactivation of a herpesvirus infection (herpes simplex virus 2) early after HSCT, and none developed EBV-PTLD. The T-cell count in the peripheral blood on day 28 was 0/microL in all 4 patients who received rabbit ATG; this was significantly less than in patients who received equine ATG (median, 174/microL; P =.001; Mann-Whitney ranked sum test). Although the numbers are limited, the time course and similarity of the 2 cases of EBV-PTLD and the effect on day 28 T-cell counts support a relationship between the development of EBV-PTLD and the administration of rabbit ATG. The differences between equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this regimen without further study.
Collapse
Affiliation(s)
- Richard A Nash
- Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Peres E, Madgie A, Abella E, Dansey R. 139EBV-associated lymphoproliferative disorder developing after conditioning with rabbit ATG. Biol Blood Marrow Transplant 2003. [DOI: 10.1016/s1083-8791(03)80140-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100:1602-10. [PMID: 12176878 PMCID: PMC2956742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023] Open
Abstract
Systemic sclerosis (SSc) is a multisystem disease of presumed autoimmune pathogenesis for which no proven effective treatment exists. High-dose immunosuppressive therapy (HDIT) has been proposed as an investigational treatment for severe autoimmune diseases. Nineteen patients with poor-prognosis SSc underwent HDIT. The median age was 40 years (range, 23-61 years), the median modified Rodnan skin score (a measure of dermal sclerosis) was 31, and the median DLCO was 57%. Conditioning therapy involved 800 cGy total body irradiation (TBI) (+/- lung shielding to approximately 200 cGy), 120 mg/kg cyclophosphamide, and 90 mg/kg equine antithymocyte globulin. CD34-selected granulocyte-colony-stimulating factor-mobilized autologous blood stem cells provided hematopoietic rescue. With median follow-up at 14.7 months, the Kaplan-Meier estimated 2-year survival rate was 79%. Three patients died of treatment complications and one of disease progression. Two of the first 8 patients had fatal regimen-related pulmonary injury, a complication not found among 11 subsequent patients who received lung shielding for TBI. Overall, internal organ functions were stable to slightly worse after HDIT, and 4 patients had progressive or nonresponsive disease. As measured by modified Rodnan skin scores and modified health assessment questionnaire disability index (mHAQ-DI) scores, significant disease responses occurred in 12 of 12 patients evaluated at 1 year after HDIT. In conclusion, though important treatment-related toxicities occurred after HDIT for SSc, modifications of initial approaches appear to reduce treatment risks. Responses in skin and mHAQ-DI scores exceed those reported with other therapies, suggesting that HDIT is a promising new therapy for SSc that should be evaluated in prospective randomized studies.
Collapse
|
47
|
Chandrasekar PH, Abraham OC, Klein J, Alangaden G, Chalasani G, Cassells L, Dansey R, Abella S, Karanes C, Peters W, Baynes R. Low infectious morbidity after intensive chemotherapy and autologous peripheral blood progenitor cell transplantation in the outpatient setting for women with breast cancer. Clin Infect Dis 2001; 32:546-51. [PMID: 11181116 DOI: 10.1086/318715] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2000] [Revised: 07/05/2000] [Indexed: 11/03/2022] Open
Abstract
Autologous peripheral blood progenitor cell (PBPC) transplantation is increasingly employed in the outpatient setting, yet data on early complications following PBPC transplantation are scant. We evaluated 105 women with high-risk primary or metastatic breast cancer who were treated at a single institution during 1996--1997. The mean duration of neutropenia (absolute neutrophil count, <500 cells/mm(3)) was 7.5 days. Twenty-nine percent of women remained afebrile throughout the neutropenic period. Of the remaining 71%, most (64 of 75) had fever of unknown origin. Infections, mostly of mild severity, occurred in 34% of women; these infections included bacteremia due to gram-positive organisms, catheter site infection, cellulitis, pneumonia, oral candidiasis, herpes simplex virus infection, and vaginitis. Fifty percent of PBPC transplant recipients required hospital admission, usually because of persistent fever; the mean duration of hospitalization was 3 days. No deaths or serious adverse events occurred. Such reduced infectious morbidity may be a consequence of minimal oral and/or gastrointestinal mucositis associated with the conditioning regimen and broad-spectrum antimicrobial prophylaxis used for this patient population.
Collapse
Affiliation(s)
- P H Chandrasekar
- Division of Infectious Diseases, Department of Internal Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Sloan AE, Dansey R, Zamorano L, Barger G, Hamm C, Diaz F, Baynes R, Wood G. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony–stimulating factor and adoptive transfer of anti-CD3–activated lymphocytes. Neurosurg Focus 2000; 9:e9. [PMID: 16817692 DOI: 10.3171/foc.2000.9.6.10] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Object
This trial was designed to determine the ability of autologous whole–tumor cell vaccines to induce cell-mediated immune responses in patients with recurrent malignant glioma, as well as to determine whether combining such vaccination with adoptive transfer of in vitro activated T lymphocytes prolongs patient survival.
Methods
Nineteen patients with recurrent malignant glioma, in whom previous external beam radiotherapy and at least one course of chemotherapy had failed were vaccinated twice with irradiated autologous whole tumor cells by using granulocyte-marcrophage colony–stimulating factor as an adjuvant. Patients then underwent leukapheresis followed by adoptive transfer of peripheral blood lymphocytes activated in vitro with anti-CD3 and interleukin-2. In vivo immune response, radiological response, clinical outcome, and survival were monitored.
Seventeen patients developed a delayed-type hypersensitivity (DTH) response to vaccination that appeared to be directed against the autologous tumor. In eight patients there was radiological evidence of a response and in five there was evidence of clinical improvement. Median survival was 12 months (range 6–28 months), and both the presence of a DTH response and the radiological response correlated with survival (p < 0.02 and p < 0.04, respectively).
Conclusions
These preliminary results suggest that autologous whole–tumor cell vaccines induce a cell-mediated immune response, which appears to be tumor specific in most patients. Furthermore, vaccination combined with adoptive immunotherapy with in vitro activated cells may induce a radiologically demonstrated tumor response and improved survival despite a condition of advanced disease and immunosuppression resulting from previous treatment or tumor burden. Further studies of immunotherapy are warranted.
Collapse
Affiliation(s)
- A E Sloan
- Department of Neurosurgery, Karmanos Cancer Institute, Detroit, Michigan, USA.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Negrin RS, Atkinson K, Leemhuis T, Hanania E, Juttner C, Tierney K, Hu WW, Johnston LJ, Shizurn JA, Stockerl-Goldstein KE, Blume KG, Weissman IL, Bower S, Baynes R, Dansey R, Karanes C, Peters W, Klein J. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 2000; 6:262-71. [PMID: 10871151 DOI: 10.1016/s1083-8791(00)70008-5] [Citation(s) in RCA: 126] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
We report here the transplantation of extensively purified "mobilized" peripheral blood CD34Thy-1 hematopoietic stem cells from 22 patients with recurrent or metastatic breast cancer. Patients were mobilized with either high-dose granulocyte colony-stimulating factor (G-CSF) alone or cyclophosphamide plus G-CSE Median purity of the stem cell product at cryopreservation was 95.3% (range, 91.1%-98.3%), and viability was 98.6% (range, 96.5%-100%). After high-dose chemotherapy with carmustine, cisplatin, and cyclophosphamide, CD34+Thy-1 cells at a median dose of 11.3 x 10(5) per kilogram (range, 4.7-163 x 10(5) per kilogram) were infused. No infusion-related toxicity was observed. Neutrophil recovery was prompt, with median absolute neutrophil count >500/microL by day 10 (range, 8-15 days) and >1000/microL by day 11 (range, 8-17 days). Median platelet recovery (>20,000/microL) was observed by day 14 (range, 9-42 days) and >50,000/microL by day 17 (range, 11-49 days). Tumor cell depletion below the limits of detection of a sensitive immunofluorescence-based assay was accomplished in all patients who had detectable tumor cells in apheresis products before processing. Although CD4+ T-cell reconstitution was slow, no unusual infections were observed. Neither early nor late graft failure was observed, and no patient required infusion of unmanipulated backup cells. At a median follow-up of approximately 1.4 years and a maximum follow-up of 2.5 years, 16 of the 22 patients remain alive, with 9 free of disease progression, and have stable blood counts. In summary, highly purified CD34+Thy-1+ cells used as the sole source of the hematopoietic graft result in rapid and sustained hematopoietic engraftment.
Collapse
Affiliation(s)
- R S Negrin
- Division of Bone Marrow Transplantation, Department of Medicine, Stanford University Medical Center, Stanford, California USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Baynes RD, Hamm C, Dansey R, Klein J, Cassells L, Karanes C, Abella E, Peters WP. Bone marrow and peripheral blood hematopoietic stem cell transplantation: focus on autografting. Clin Chem 2000; 46:1239-51. [PMID: 10926918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
This review focuses on certain of the principles involved in high-dose chemotherapy and radiation therapy along with autologous hematopoietic stem cell transplantation for the treatment of certain malignancies. In addition, the evidence, wherever possible based on randomized data, for the application of this approach in certain malignancies is reviewed. The malignancies highlighted include acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma, Hodgkin disease, and breast cancer.
Collapse
Affiliation(s)
- R D Baynes
- Bone Marrow Transplant Program, Barbara Ann Karmanos Cancer Institute at Wayne State University, 3990 John R, 4 Brush South, Detroit, MI 48201, USA.
| | | | | | | | | | | | | | | |
Collapse
|